Results preview: J&J, the Juggernaut that won’t spill its load
This article was originally published in Scrip
Executive Summary
Johnson & Johnson will kick off the big pharma financial reporting season this week, announcing its results on Tuesday 22 January. The healthcare behemoth is looking increasingly anomalous as a diversified conglomerate following Abbott Laboratories' spin-off of its pharma business, AbbVie, and Pfizer's recent moves to divest or separate diverse elements of its business, selling nutrition to Nestlé and launching an IPO for its animal health business Zoetis.